RT Journal Article
SR Electronic
T1 847 Optimal dose selection of ADG126 (a masked anti-CTLA-4 SAFEbody®) with significantly widened therapeutic index compared to ipilimumab in combination with anti-PD-1 antibodies informed by QSP modeling
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP A945
OP A945
DO 10.1136/jitc-2023-SITC2023.0847
VO 11
IS Suppl 1
A1 Zheng, Songmao
A1 Sun, Meng
A1 Wang, Xin
A1 Skinner, John J
A1 Liu, Guizhong
A1 She, Kristine
A1 Xu, Jiangchun
A1 Du, Felix
A1 Li, Yan
A1 Zha, Jiping
A1 Luo, Peter
YR 2023
UL http://jitc.bmj.com/content/11/Suppl_1/A945.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.